Engineered donor cells could outsmart relapsed myeloma

This trial tests whether a specially engineered donor stem cell transplant, called Orca-Q, can safely treat people with high-risk multiple myeloma that has returned or not responded to prior therapy. The transplant uses donor blood-forming cells and immune cells, with certain T cells removed to reduce the risk of graft-versus-host disease, a common complication. Before the transplant, patients receive chemotherapy to prepare their body. The goal is to see if this approach can help destroy remaining cancer cells and lead to lasting remission.